MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it has completed enrollment in the first of two pivotal phase 3 studies of Qnexa™ in obese patients. The EQUIP study (OB-302) has enrolled over 1,250 morbidly obese patients with a Body Mass Index (“BMI”) that equals or exceeds 35. The co-primary endpoints for these studies are the mean percent weight loss and the percentage of subjects achieving weight loss of 5% or more.
